NCT03517449 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 827
- units
- Participants
- groups
- description
- Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.
- id
- BG000
- title
- Lenvatinib 20 mg + Pembrolizumab 200 mg
- description
- Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
- id
- BG001
- title
- Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.1
- value
- 63.2
- group Id
- BG001
- spread
- 9.2
- value
- 63.8
- group Id
- BG002
- spread
- 9.1
- value
- 63.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- In utero
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Preterm newborn infants (gestational age < 37 wks)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Newborns (0-27 days)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Infants and toddlers (28 days-23 months)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Children (2-11 years)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Adolescents (12-17 years)
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 204
- group Id
- BG002
- value
- 410
- title
- Adults (18-64 years)
- measurements
- group Id
- BG000
- value
- 205
- group Id
- BG001
- value
- 210
- group Id
- BG002
- value
- 415
- title
- From 65-84 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- 85 years and over
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 827
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 132
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 309
- group Id
- BG001
- value
- 288
- group Id
- BG002
- value
- 597
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 98
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 92
- group Id
- BG002
- value
- 177
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 31
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 261
- group Id
- BG001
- value
- 247
- group Id
- BG002
- value
- 508
- title
- White
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 20
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 79
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 246
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 487
- title
- 0 = Fully active; no performance restrictions
- measurements
- group Id
- BG000
- value
- 165
- group Id
- BG001
- value
- 175
- group Id
- BG002
- value
- 340
- title
- 1 = Limited activity, ambulant, can-do light work
- description
- The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care; 3, capable of limited self-care; 4, completely disabled; and 5, dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 363
- title
- Participants with pelvic radiation
- measurements
- group Id
- BG000
- value
- 235
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 464
- title
- Participants without pelvic radiation
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Prior history of pelvic radiation
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 474
- title
- Region 1
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 353
- title
- Region 2
- description
- Participants in region 1 were included from Europe,USA,Canada,Australia,New Zealand,Israel. Participants in region 2 were included from rest of the world.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 346
- group Id
- BG001
- value
- 351
- group Id
- BG002
- value
- 697
- title
- Proficient MMR (pMMR)
- measurements
- group Id
- BG000
- value
- 65
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 130
- title
- Deficient (dMMR)
- description
- The mismatch repair system (MMR) is a crucial mechanism in DNA repair that identifies and corrects errors that occur during DNA replication and recombination. pMMR indicates that the MMR system is functioning properly, which is advantageous for maintaining genomic stability and reducing mutation accumulation. In contrast, dMMR signifies a deficiency in the MMR system, leading to increased mutation rates and a higher risk of tumorigenesis. pMMR and dMMR were based on actual MMR status defined by immunohistochemistry (IHC) performed on tumor tissue.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Mismatch repair (MMR) status
- unit Of Measure
- Participants
- population Description
- The Intention-to-treat (ITT) population included all randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 827
- units
- Participants
- groups
- description
- Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.
- id
- BG000
- title
- Lenvatinib 20 mg + Pembrolizumab 200 mg
- description
- Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
- id
- BG001
- title
- Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.1
- value
- 63.2
- group Id
- BG001
- spread
- 9.2
- value
- 63.8
- group Id
- BG002
- spread
- 9.1
- value
- 63.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- In utero
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Preterm newborn infants (gestational age < 37 wks)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Newborns (0-27 days)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Infants and toddlers (28 days-23 months)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Children (2-11 years)
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Adolescents (12-17 years)
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 204
- group Id
- BG002
- value
- 410
- title
- Adults (18-64 years)
- measurements
- group Id
- BG000
- value
- 205
- group Id
- BG001
- value
- 210
- group Id
- BG002
- value
- 415
- title
- From 65-84 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- 85 years and over
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 827
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 132
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 309
- group Id
- BG001
- value
- 288
- group Id
- BG002
- value
- 597
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 98
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 92
- group Id
- BG002
- value
- 177
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 31
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 261
- group Id
- BG001
- value
- 247
- group Id
- BG002
- value
- 508
- title
- White
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 20
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 79
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 246
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 487
- title
- 0 = Fully active; no performance restrictions
- measurements
- group Id
- BG000
- value
- 165
- group Id
- BG001
- value
- 175
- group Id
- BG002
- value
- 340
- title
- 1 = Limited activity, ambulant, can-do light work
- description
- The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care; 3, capable of limited self-care; 4, completely disabled; and 5, dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 363
- title
- Participants with pelvic radiation
- measurements
- group Id
- BG000
- value
- 235
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 464
- title
- Participants without pelvic radiation
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Prior history of pelvic radiation
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 474
- title
- Region 1
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 176
- group Id
- BG002
- value
- 353
- title
- Region 2
- description
- Participants in region 1 were included from Europe,USA,Canada,Australia,New Zealand,Israel. Participants in region 2 were included from rest of the world.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 346
- group Id
- BG001
- value
- 351
- group Id
- BG002
- value
- 697
- title
- Proficient MMR (pMMR)
- measurements
- group Id
- BG000
- value
- 65
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 130
- title
- Deficient (dMMR)
- description
- The mismatch repair system (MMR) is a crucial mechanism in DNA repair that identifies and corrects errors that occur during DNA replication and recombination. pMMR indicates that the MMR system is functioning properly, which is advantageous for maintaining genomic stability and reducing mutation accumulation. In contrast, dMMR signifies a deficiency in the MMR system, leading to increased mutation rates and a higher risk of tumorigenesis. pMMR and dMMR were based on actual MMR status defined by immunohistochemistry (IHC) performed on tumor tissue.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Mismatch repair (MMR) status
- unit Of Measure
- Participants
- population Description
- The Intention-to-treat (ITT) population included all randomized participants.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle